Pfizer (PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 revenue guidance of $61 billion to ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...

Pfizer (PFE) delivered earnings and revenue surprises of +34.48% and +6.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Pfizer said the revised profit outlook reflects strong results in the first half of the year, improved cost efficiency, a ...

Pfizer's strong EPS surprise streak and positive earnings revisions are encouraging, but patent cliff risks remain a major ...

Pfizer, the U.S.-based pharmaceutical giant, revealed its second-quarter financial results on Tuesday, showcasing a robust 10 ...

Pfizer's stock soared following robust sales of COVID-19 products and key drugs, leading to stronger-than-expected earnings and an increased profit forecast for 2025.

Pfizer PFE reported second-quarter 2025 adjusted earnings per share of 78 cents, which comprehensively beat the Zacks ...

Pfizer stock rises after a strong Q2, boosted by cost savings, pipeline progress, and an upgraded 2025 profit outlook.

Pfizer's stock surged following a report of stronger-than-expected earnings, driven by robust sales of COVID-19 products and ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

As McDonald’s prepares to report its next earnings, traders should pay close attention to whether same-store sales in the U.S ...